Patents Assigned to DRK-Blutspendedienst Baden-Wurttemberg
-
Publication number: 20230407263Abstract: The present invention pertains to an improved mesenchymal stromal cell (MSC) preparation and a method for producing the same. The invention provides a new strategy to isolate MSC from bone marrow mononuclear cells (BM-MNCs) by pooling BM-MNCs of multiple unrelated (third-party) bone marrow donors. The MSC preparation manufactured in accordance with the methodology of the invention is characterized by a stable proliferative capability and an increased immunosuppressive potential when compared to individual donor MSC preparations or a pool of individual MSCs generated from multiple donors. The MSCs prepared according to the invention are particularly useful for medical applications such as the treatment of graft-versus-host disease (GvHD) in recipients with hematopoietic stem cell transplants, patients with autoimmune disorders and as a cell-based therapy in regenerative medicine.Type: ApplicationFiled: February 2, 2023Publication date: December 21, 2023Applicants: Johann Wolfgang Goethe-Universität, Frankfurt Am Main, DRK BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBHInventors: Peter Bader, Selim Kuci, Zyrafete Kuci, Halvard Bönig
-
Patent number: 11208645Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.Type: GrantFiled: February 6, 2020Date of Patent: December 28, 2021Assignee: DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbHInventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
-
Patent number: 10883097Abstract: The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.Type: GrantFiled: October 1, 2018Date of Patent: January 5, 2021Assignee: DRK-BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBHInventors: Erhard Seifried, Jörg Schüttrumpf
-
Patent number: 10604749Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.Type: GrantFiled: May 16, 2018Date of Patent: March 31, 2020Assignee: DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbHInventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
-
Patent number: 10550197Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.Type: GrantFiled: June 18, 2015Date of Patent: February 4, 2020Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbHInventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
-
Patent number: 10472608Abstract: The present invention pertains to an improved mesenchymal stromal cell (MSC) preparation and a method for producing the same. The invention provides a new strategy to isolate MSC from bone marrow mononuclear cells (BM-MNCs) by pooling BM-MNCs of multiple unrelated (third-party) bone marrow donors. The MSC preparation manufactured in accordance with the methodology of the invention is characterized by a stable proliferative capability and an increased immunosuppressive potential when compared to individual donor MSC preparations or a pool of individual MSCs generated from multiple donors. The MSCs prepared ac- cording to the invention are particularly useful for medical applications such as the treatment of graft-versus-host disease (GvHD) in recipients with hematopoietic stem cell transplants, patients with autoimmune disorders and as a cell-based therapy in regenerative medicine.Type: GrantFiled: July 14, 2015Date of Patent: November 12, 2019Assignees: JOHANN WOLFGANG GOETHE—UNIVERSITÄT, DRK BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBHInventors: Peter Bader, Selim Kuci, Zyrafete Kuci, Halvard Bönig
-
Patent number: 10125357Abstract: The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.Type: GrantFiled: July 28, 2009Date of Patent: November 13, 2018Assignee: DRK-BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBHInventors: Erhard Seifried, Jörg Schüttrumpf
-
Publication number: 20180282427Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErhB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying au ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.Type: ApplicationFiled: February 20, 2018Publication date: October 4, 2018Applicants: CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS, DRK BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBHInventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
-
Patent number: 10000748Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.Type: GrantFiled: December 3, 2014Date of Patent: June 19, 2018Assignee: DRK-BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBHInventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
-
Patent number: 9920132Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.Type: GrantFiled: May 19, 2017Date of Patent: March 20, 2018Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK Blutspendedienst Baden-Wurttemberg-Hessen gGmbHInventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
-
Patent number: 9217181Abstract: The present invention relates to a nucleic acid molecular structure representing the Rhesus genes locus comprising the RHD, SMP1 and RHCE genes and/or the Rhesus box(es), preferably the hybrid Rhesus box, the upstream Rhesus bar and/or the downstream Rhesus box. Furthermore, the invention relates to a process for the specific detection of the common RHD negative haplotypes. The invention further relates to the detection of RHD positive hyplotypes in D-negative individuals. Various mutations in the RHD gene have been identified that allow for the development of diagnostic tools. The invention also relates to oligonucleotides, that specifically hybridize to the hybrid box, preferably the breakpoint or breakpoint region or to the upstream and downstream Rhesus boxes. Additionally, the invention relates to kits comprising or employing the above recited compounds of the invention.Type: GrantFiled: February 23, 2009Date of Patent: December 22, 2015Assignee: DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GEMEINNUTZIGE GMBHInventors: Willy A. Flegel, Franz F. Wagner
-
Patent number: 9034573Abstract: The RH blood group antigens derive from two genes, RHD and RHCE, that are located at chromosomal position 1p34.1-1p36. In whites, a “cde” haplotype with a deletion of the whole RHD gene occurs with a frequency of about 40%. The relative position of the two RH genes and the location of the RHD deletion was previously unknown. A model for the RH locus was developed using RHD- and RHCE-related nucleotide sequences deposited in nucleotide sequence databases along with PCR and nucleotide sequencing. The open reading frames of both RH genes had opposite orientations. The 3? ends of the genes faced each other and were separated by about 30,000 base pairs (bp) that contained the SMP1 gene. The RHD gene was flanked by two DNA segments, dubbed Rhesus boxes, that had about 9,000 bp length, 98.6% homology, and identical orientation. The Rhesus box contained the RHD deletion occurring within a stretch of 1,463 bp of identity. A PCR-SSP and a PCR-RFLP for specific detection of the RHD deletion was devised.Type: GrantFiled: October 31, 2000Date of Patent: May 19, 2015Assignee: DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GEMEINNUTZIGE GMBHInventors: Willy A. Flegel, Franz F. Wagner
-
Patent number: 7252949Abstract: The present invention relates to novel nucleic acid molecules encoding a Rhesus D antigen contributing to the weak D phenotype which are characterized by one or a combination of missense mutations or by a gene conversion involving exons 6 to 9 of the RHD and RHCE genes. The present invention further relates to vectors comprising the nucleic acid molecules of the invention, to hosts transformed with said vectors, to proteins encoded by said nucleic acid molecules and to methods of producing such polypeptides. The fact that missense mutations and the conversion referred to above can be directly correlated to the weak D phenotype has a significant impact on the routine testing of blood samples. For example, oligonucleotides and antibodies can now be designed that generally allow the detection of weak D phenotypes in a sample. Such oligonucleotides, antibodies as well as a variety of diagnostic methods all fall within the scope of the present invention.Type: GrantFiled: August 10, 2005Date of Patent: August 7, 2007Assignee: DRK-Blutspendedienst Baden-Wurttemberg-Hessen gemeinnutzige GmbHInventors: Willy A. Flegel, Franz F. Wagner
-
Patent number: 7241445Abstract: Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis C virus (HCV) E2 glycoprotein and capable of neutralizing HCV infection in vivo in an animal model, as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention and treatment of HCV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HCV E2 antibodies are transformed in vitro by Epstein-Barr virus and then fused with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HCV E2 glycoprotein.Type: GrantFiled: July 25, 2001Date of Patent: July 10, 2007Assignee: DRK-Blutspendedienst Baden-WurttembergInventors: Bernhard Kubanek, Marcia Da Silva Cardoso, Karl Sifmoneit, Shlomo Dagan, Rachel Eren
-
Publication number: 20060104987Abstract: The present invention relates to novel nucleic acid molecules encoding a Rhesus D antigen contributing to the weak D phenotype which are characterized by one or a combination of missense mutations or by a gene conversion involving exons 6 to 9 of the RHD and RHCE genes. The present invention further relates to vectors comprising the nucleic acid molecules of the invention, to hosts transformed with said vectors, to proteins encoded by said nucleic acid molecules and to methods of producing such polypeptides. The fact that missense mutations and the conversion referred to above can be directly correlated to the weak D phenotype has a significant impact on the routine testing of blood samples. For example, oligonucleotides and antibodies can now be designed that generally allow the detection of weak D phenotypes in a sample. Such oligonucleotides, antibodies as well as a variety of diagnostic methods all fall within the scope of the present invention.Type: ApplicationFiled: August 10, 2005Publication date: May 18, 2006Applicant: DRK Blutspendedienst Baden-Wurttemberg gGmbHInventors: Willy Flegel, Franz Wagner